COMMUNIQUÉS West-GlobeNewswire

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
10/11/2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has [...]
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
10/11/2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027 LONDON, [...]
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data from the HOPE-3 [...]
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control [...]
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
10/11/2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases [...]
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
10/11/2025
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B- [...]
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
10/11/2025
Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean [...]
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
10/11/2025
Completed the sale of FibroGen China to AstraZeneca for approximately $220 million Initiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in [...]
Health Catalyst Reports Third Quarter 2025 Results
10/11/2025
SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
10/11/2025
Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; [...]
Harrow Announces Third Quarter 2025 Financial Results
10/11/2025
Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million [...]
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch
10/11/2025
On track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay’s head-to-head data [...]
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
10/11/2025
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, [...]
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule
10/11/2025
Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma - among the most fatal cancers worldwide SARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. ( [...]
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
10/11/2025
ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord [...]
Outset Medical Reports Third-Quarter Results
10/11/2025
SAN JOSE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported [...]
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
10/11/2025
Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, [...]
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance
10/11/2025
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and [...]
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
10/11/2025
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA [...]

Pages